CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin. This dossier gathers the 0 products (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Signals via TRAF proteins to NF-κB; shed soluble CD30 is a serum marker. Sparse normal expression outside activated T and B cells.
- Classical Hodgkin lymphoma (~100%)
- Anaplastic large-cell lymphoma
- Peripheral T-cell lymphoma (subset)
- Primary mediastinal B-cell lymphoma
- Embryonal carcinoma
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| ECHELON-1 NCT01712490 | 3 | Positive | Untreated stage III-IV classical Hodgkin lymphoma: brentuximab vedotin + AVD vs ABVD | 6-year OS 93.9% vs 89.4%, HR 0.59. |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →- SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults · New England Journal of Medicine 2024
- ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma · New England Journal of Medicine 2018
Query for this target: (TITLE:"CD30" OR ABSTRACT:"CD30" OR TITLE:"TNFRSF8" OR ABSTRACT:"TNFRSF8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD30, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd30.json. Licence CC BY 4.0.